Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment LYT-200 is currently ...

Blood Cancer United®, formerly The Leukemia & Lymphoma Society, announced today that the first patient has received treatment in a new sub-study of its Beat AML® Master Clinical Trial (Beat AML).

Pediatric acute myeloid leukemia (AML) is one of the most common acute leukemias in children. While treatment outcomes have ...

Acute myeloid leukemia (AML) is a type of blood and bone marrow cancer. AML can affect people of any age, but it is most common in adults. AML occurs when bone marrow produces abnormal blood cells, ...

The blood cancers acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) are extremely challenging to treat. While advances in immunotherapy have cured many patients with other blood cancers, ...

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia by identifying the blood cancer's reliance on a specific signaling pathway ...

A new generation of targeted treatments and gentler chemotherapy options for older adults with a new diagnosis of acute myeloid leukemia (AML) is driving better survival and cure rates. Led by Mikkael ...

New research co-led by Indiana University School of Medicine scientists has exposed a vulnerability in acute myeloid leukemia ...

Imagine conquering childhood cancer, only to find out that years down the road your heart may fail. Unfortunately, many children who have battled cancer face this reality. While often lifesaving, the ...

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma To our knowledge, this is the ...